Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

26.46
+0.32001.22%
Post-market: 26.06-0.4000-1.51%17:43 EDT
Volume:5.86M
Turnover:149.84M
Market Cap:3.31B
PE:122.83
High:26.62
Open:25.95
Low:24.35
Close:26.14
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:2.02
T/O Rate:5.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:15.00
PE(LYR):-208.58

Loading ...

Arcutis director Howard Welgus sells 7,144 shares for $164,203.54

Reuters
·
May 06

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 62.67%, and institutional views are bullish

Earnings Agent
·
Apr 30

Arcutis submits FDA sNDA for Zoryve cream use in infants with atopic dermatitis

Reuters
·
Apr 27

Arcutis Submits Supplemental New Drug Application to the FDA for Zoryve® (Roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

THOMSON REUTERS
·
Apr 27

A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Pediatric Guidelines For ZORYVE

Simply Wall St.
·
Apr 25

Arcutis’ Zoryve® (Roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

THOMSON REUTERS
·
Apr 22

Arcutis Biotherapeutics announces annual shareholder meeting

Reuters
·
Apr 22

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Apr 14

Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next

Simply Wall St.
·
Apr 07

Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million

Reuters
·
Apr 04

Arcutis management to present at Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 01

How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story

Simply Wall St.
·
Mar 30

Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

TIPRANKS
·
Mar 29

Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis

Reuters
·
Mar 28